| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Income (loss) before income taxes | 1,155 | 247 | 6,112 | -20,039 |
| Income tax expense | 615 | - | - | - |
| Net income (loss) | 540 | 247 | 6,112 | - |
| Net loss, diluted | - | - | - | -20,039 |
| Comprehensive income (loss) | 540 | 247 | 6,112 | - |
| Basic (in dollars per share) | 0 | 0 | 0.03 | -0.1 |
| Basic (in shares) | 264,786,432 | 262,565,500 | 235,497,720 | 210,348,459 |
| Diluted (in dollars per share) | 0 | 0 | 0.03 | -0.1 |
| Diluted (in shares) | 274,372,722 | 271,104,020 | 241,602,853 | 210,348,459 |
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)